Aridis Pharmaceuticals Inc. Stock News

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic

LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies

Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health

Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies fo

LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed si

Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.

LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies

Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.

Aridis (ARDS) stock jumps 115% after the company reports reaching an agreement with the FDA on its proposed study on AR-301 as an adjunctive treatment for hospital-acquired pneumonia.

Penny stocks, often defined as shares trading for less than $5, present a unique opportunity for investors seeking high potential returns. Despite their low market price, these stocks can offer signif

Whether you're trading penny stocks or higher-priced company shares, everyone wants to gain an edge. In the stock market today, there are plenty of catalysts to consider.

Aridis Pharmaceuticals (ADRS) meets primary and secondary endpoints in a phase IIa study on AR-501 for treating cystic fibrosis.

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -4,100% and 96.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Aridis Pharmaceuticals (ARDS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreeme